HomeCompareGTHR vs EQR

GTHR vs EQR: Dividend Comparison 2026

GTHR yields 2000000.00% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GTHR wins by $4.879226400974806e+39M in total portfolio value
10 years
GTHR
GTHR
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full GTHR calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — GTHR vs EQR

📍 GTHR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGTHREQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GTHR + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GTHR pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GTHR
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, GTHR beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GTHR + EQR for your $10,000?

GTHR: 50%EQR: 50%
100% EQR50/50100% GTHR
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

GTHR
No analyst data
Altman Z
-44119.1
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GTHR buys
0
EQR buys
0
No recent congressional trades found for GTHR or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGTHREQR
Forward yield2000000.00%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$4.879226400974806e+39M$47.8K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$5,475.61
Total dividends collected$4.879195005460081e+39M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: GTHR vs EQR ($10,000, DRIP)

YearGTHR PortfolioGTHR Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,380$679.82+$200.00MGTHR
2$3,738,731,768,458$3,738,517,757,009.35$13,014$837.25+$3738731.76MGTHR
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,961$1,036.20+$65315062866.92MGTHR
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$17,297$1,289.22+$1066400830062625.00MGTHR
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$20,121$1,613.15+$16272182796453826560.00MGTHR
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$23,561$2,030.84+$2.3205424011366188e+23MGTHR
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$27,783$2,573.54+$3.0927990661046884e+27MGTHR
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$33,013$3,284.39+$3.8524105697352695e+31MGTHR
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$39,547$4,223.51+$4.484688260147987e+35MGTHR
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$47,791$5,475.61+$4.879226400974806e+39MGTHR

GTHR vs EQR: Complete Analysis 2026

GTHRStock

GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company's Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. GeneThera, Inc. is based in Westminster, Colorado.

Full GTHR Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this GTHR vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GTHR vs SCHDGTHR vs JEPIGTHR vs OGTHR vs KOGTHR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.